RESUMEN
Human immunodeficiency virus (HIV) type 1 Vpu is an integral membrane protein with a unique affinity for betaTrCP (TrCP), a key member of the SkpI-Cullin-F-box E3 ubiquitin ligase complex that is involved in the regulated degradation of cellular proteins, including IkappaB. Remarkably, Vpu is resistant to TrCP-mediated degradation and competitively inhibits TrCP-dependent degradation of IkappaB, resulting in the suppression of nuclear factor (NF)-kappaB activity in Vpu-expressing cells. We now report that Vpu, through its interaction with TrCP, potently contributes to the induction of apoptosis in HIV-infected T cells. Vpu-induced apoptosis is specific and independent of other viral proteins. Mutation of a TrCP-binding motif in Vpu abolishes its apoptogenic property, demonstrating a close correlation between this property of Vpu and its ability to inhibit NF-kappaB activity. The involvement of NF-kappaB in Vpu-induced apoptosis is further supported by the finding that the levels of antiapoptotic factors Bcl-xL, A1/Bfl-1, and TNF receptor-associated factor (TRAF)1, all of which are expressed in an NF-kappaB-dependent manner, are reduced and, at the same time, levels of active caspase-3 are elevated. Thus, Vpu induces apoptosis through activation of the caspase pathway by way of inhibiting the NF-kappaB-dependent expression of antiapoptotic genes.
Asunto(s)
Apoptosis , VIH-1/metabolismo , FN-kappa B/metabolismo , Biosíntesis de Proteínas , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Proteínas Reguladoras y Accesorias Virales/metabolismo , Sitios de Unión , Antígenos CD4/genética , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/metabolismo , Caspasa 3 , Caspasas/metabolismo , Línea Celular Transformada , Activación Enzimática , Proteínas de Unión al GTP/metabolismo , Expresión Génica , Productos del Gen env/metabolismo , VIH-1/fisiología , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Células Jurkat , Antígenos de Histocompatibilidad Menor , Péptido Sintasas/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Ligasas SKP Cullina F-box , Factor 1 Asociado a Receptor de TNF , Factor de Necrosis Tumoral alfa/farmacología , Proteínas Reguladoras y Accesorias Virales/genética , Proteínas Reguladoras y Accesorias Virales/fisiología , Proteína bcl-X , Proteínas con Repetición de beta-TransducinaRESUMEN
The human immunodeficiency virus type 1 (HIV-1) Vif protein plays a critical role in the production of infectious virions. Previous studies have demonstrated the presence of small amounts of Vif in virus particles. However, Vif packaging was assumed to be nonspecific, and its functional significance has been questioned. We now report that packaging of Vif is dependent on the packaging of viral genomic RNA in both permissive and restrictive HIV-1 target cells. Mutations in the nucleocapsid zinc finger domains that abrogate packaging of viral genomic RNA abolished packaging of Vif. Additionally, an RNA packaging-defective virus exhibited significantly reduced packaging of Vif. Finally, deletion of a putative RNA-interacting domain in Vif abolished packaging of Vif into virions. Virion-associated Vif was resistant to detergent extraction and copurified with components of the viral nucleoprotein complex and functional reverse transcription complexes. Thus, Vif is specifically packaged into virions as a component of the viral nucleoprotein complex. Our data suggest that the specific association of Vif with the viral nucleoprotein complex might be functionally significant and could be a critical requirement for infectivity of viruses produced from restrictive host cells.
Asunto(s)
Productos del Gen vif/química , VIH-1/química , ARN Viral/química , Productos del Gen vif/fisiología , Genoma Viral , Infecciones por VIH/virología , VIH-1/fisiología , Células HeLa , Humanos , Mutación , Nucleoproteínas/química , Nucleoproteínas/fisiología , Unión Proteica , ARN Viral/fisiología , Ensamble de Virus , Dedos de Zinc , Productos del Gen vif del Virus de la Inmunodeficiencia HumanaRESUMEN
The human immunodeficiency virus type 1 (HIV-1) Vpu protein binds to the CD4 receptor and induces its degradation by cytosolic proteasomes. This process involves the recruitment of human betaTrCP (TrCP), a key member of the SkpI-Cdc53-F-box E3 ubiquitin ligase complex that specifically interacts with phosphorylated Vpu molecules. Interestingly, Vpu itself, unlike other TrCP-interacting proteins, is not targeted for degradation by proteasomes. We now report that, by virtue of its affinity for TrCP and resistance to degradation, Vpu, but not a phosphorylation mutant unable to interact with TrCP, has a dominant negative effect on TrCP function. As a consequence, expression of Vpu in HIV-infected T cells or in HeLa cells inhibited TNF-alpha-induced degradation of IkappaB-alpha. Vpu did not inhibit TNF-alpha-mediated activation of the IkappaB kinase but instead interfered with the subsequent TrCP-dependent degradation of phosphorylated IkappaB-alpha. This resulted in a pronounced reduction of NF-kappaB activity. We also observed that in cells producing Vpu-defective virus, NF-kappaB activity was significantly increased even in the absence of cytokine stimulation. However, in the presence of Vpu, this HIV-mediated NF-kappaB activation was markedly reduced. These results suggest that Vpu modulates both virus- and cytokine-induced activation of NF-kappaB in HIV-1-infected cells.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas de Unión al GTP/metabolismo , VIH-1/fisiología , Proteínas I-kappa B , FN-kappa B/metabolismo , Proteínas Reguladoras y Accesorias Virales/metabolismo , Antígenos CD4/fisiología , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD4-Positivos/virología , Proteínas Portadoras/metabolismo , Línea Celular , Cisteína Endopeptidasas/metabolismo , Genes vpu , VIH-1/genética , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Cinética , Modelos Biológicos , Complejos Multienzimáticos/metabolismo , Inhibidor NF-kappaB alfa , FN-kappa B/antagonistas & inhibidores , Fosforilación , Regiones Promotoras Genéticas/efectos de los fármacos , Complejo de la Endopetidasa Proteasomal , Proteínas Recombinantes de Fusión/metabolismo , Tetraciclina/farmacología , Factor de Necrosis Tumoral alfa/farmacología , Proteínas con Repetición de beta-TransducinaAsunto(s)
Productos del Gen nef/fisiología , Productos del Gen vif/fisiología , Productos del Gen vpr/fisiología , VIH-1/fisiología , Proteínas Reguladoras y Accesorias Virales/fisiología , Antígenos CD4/análisis , Ciclo Celular , Citoesqueleto/química , Antígenos de Histocompatibilidad Clase I/análisis , Proteínas del Virus de la Inmunodeficiencia Humana , Transactivadores/fisiología , Productos del Gen nef del Virus de la Inmunodeficiencia Humana , Productos del Gen vif del Virus de la Inmunodeficiencia Humana , Productos del Gen vpr del Virus de la Inmunodeficiencia HumanaRESUMEN
The N-terminal alpha-helix domain of the human immunodeficiency virus type 1 (HIV-1) Nef protein plays important roles in enhancement of viral infectivity, virion incorporation of Nef, and the down-regulation of major histocompatibility complex class I (MHC-I) expression on cell surfaces. In this study, we demonstrated that Met 20 in the alpha-helix domain was indispensable for the ability of Nef to modulate MHC-I expression but not for other events. We also showed that Met 20 was unnecessary for the down-regulation of CD4. These findings indicate that the region governing MHC-I down-regulation is proximate in the alpha-helix domain but is dissociated functionally from that determining enhancement of viral infectivity, virion incorporation of Nef, and CD4 down-regulation.
Asunto(s)
Antígenos CD4/biosíntesis , Regulación hacia Abajo , Productos del Gen nef/metabolismo , Genes MHC Clase I , VIH-1/fisiología , Metionina/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Células Cultivadas , Productos del Gen nef/genética , VIH-1/genética , VIH-1/metabolismo , Células HeLa , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/virología , Metionina/genética , Datos de Secuencia Molecular , Virión , Productos del Gen nef del Virus de la Inmunodeficiencia HumanaRESUMEN
Vpu is an 81-residue membrane protein encoded by the HIV-1 genome. NMR experiments show that the protein folds into two distinct domains, a transmembrane hydrophobic helix and a cytoplasmic domain with two in-plane amphipathic alpha-helices separated by a linker region. Resonances in one-dimensional solid-state NMR spectra of uniformly (15)N labeled Vpu are clearly segregated into two bands at chemical shift frequencies associated with NH bonds in a transmembrane alpha-helix, perpendicular to the membrane surface, and with NH bonds in the cytoplasmic helices parallel to the membrane surface. Solid-state NMR spectra of truncated Vpu(2-51) (residues 2-51), which contains the transmembrane alpha-helix and the first amphipathic helix of the cytoplasmic domain, and of a construct Vpu(28-81) (residues 28-81), which contains only the cytoplasmic domain, support this structural model of Vpu in the membrane. Full-length Vpu (residues 2-81) forms discrete ion-conducting channels of heterogeneous conductance in lipid bilayers. The most frequent conductances were 22 +/- 3 pS and 12 +/- 3 pS in 0.5 M KCl and 29 +/- 3 pS and 12 +/- 3 pS in 0.5 M NaCl. In agreement with the structural model, truncated Vpu(2-51), which has the transmembrane helix, forms discrete channels in lipid bilayers, whereas the cytoplasmic domain Vpu(28-81), which lacks the transmembrane helix, does not. This finding shows that the channel activity is associated with the transmembrane helical domain. The pattern of channel activity is characteristic of the self-assembly of conductive oligomers in the membrane and is compatible with the structural and functional findings.
Asunto(s)
VIH-1/química , Proteínas Reguladoras y Accesorias Virales/química , Secuencia de Aminoácidos , Antígenos CD4/metabolismo , VIH-1/genética , Proteínas del Virus de la Inmunodeficiencia Humana , Canales Iónicos/química , Membrana Dobles de Lípidos/química , Espectroscopía de Resonancia Magnética , Datos de Secuencia Molecular , Proteínas Reguladoras y Accesorias Virales/fisiologíaRESUMEN
One of the hallmarks of human immunodeficiency virus type I (HIV-1) infection is the rapid removal of the viral receptor CD4 from the cell surface. This remarkably efficient receptor interference requires the activity of three separate viral proteins: Env, Vpu, and Nef. We have investigated whether this unusually tight interference on cell surface CD4 expression had a more essential function during the viral life cycle than simply preventing superinfection. We now report that the removal of cell surface CD4 is required for optimal virus production by HIV-1. Indeed, maintenance of CD4 surface expression in infected cells lead to a 3-5-fold decrease in viral particle production. This effect was not due to the formation of intracellular complexes between CD4 and the gp160 viral envelope precursor but instead required the presence of CD4 at the cell surface and was specifically mediated by CD4 but not closely related plasma membrane receptors. The finding that CD4 had no significant effect on particle release by a Vpu-deficient variant indicates that CD4 acts by inhibiting the particle release-promoting activity of Vpu. Co-immunoprecipitation experiments further showed that CD4 and Vpu physically interact at the cell surface, suggesting that CD4 might inhibit Vpu activity by disrupting its oligomeric structure.
Asunto(s)
Antígenos de Superficie/fisiología , Antígenos CD4/fisiología , VIH-1/fisiología , Proteínas Reguladoras y Accesorias Virales/antagonistas & inhibidores , Virión/fisiología , Membrana Celular/inmunología , Membrana Celular/virología , Citoplasma/inmunología , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , HumanosRESUMEN
The present study was undertaken to examine structural features of L-chicoric acid (3) which are important for potency against purified HIV-1 integrase and for reported cytoprotective effects in cell-based systems. Through a progressive series of analogues, it was shown that enantiomeric D-chicoric acid (4) retains inhibitory potency against purified integrase equal to its L-counterpart and further that removal of either one or both carboxylic functionalities results in essentially no loss of inhibitory potency. Additionally, while two caffeoyl moieties are required, attachment of caffeoyl groups to the central linking structure can be achieved via amide or mixed amide/ester linkages. More remarkable is the finding that blockage of the catechol functionality through conversion to tetraacetate esters results in almost no loss of potency, contingent on the presence of at least one carboxyl group on the central linker. Taken as a whole, the work has resulted in the identification of new integrase inhibitors which may be regarded as bis-caffeoyl derivatives of glycidic acid and amino acids such as serine and beta-aminoalanine. The present study also examined the reported ability of chicoric acid to exert cytoprotective effects in HIV-infected cells. It was demonstrated in target and cell-based assays that the chicoric acids do not significantly inhibit other targets associated with HIV-1 replication, including reverse transcription, protease function, NCp7 zinc finger function, or replication of virus from latently infected cells. In CEM cells, for both the parent chicoric acid and selected analogues, antiviral activity was observable under specific assay conditions and with high dependence on the multiplicity of viral infection. However, against HIV-1- and HIV-2-infected MT-4 cells, the chicoric acids and their tetraacetylated esters exhibited antiviral activity (50% effective concentration (EC50) ranging from 1.7 to 20 microM and 50% inhibitory concentration (IC50) ranging from 40 to 60 microM).
Asunto(s)
Fármacos Anti-VIH/farmacología , Ácidos Cafeicos , Inhibidores de Integrasa VIH/farmacología , Integrasa de VIH/metabolismo , Succinatos/síntesis química , Animales , Línea Celular , Evaluación Preclínica de Medicamentos , VIH-1/efectos de los fármacos , VIH-2/efectos de los fármacos , Humanos , Estereoisomerismo , Relación Estructura-Actividad , Succinatos/química , Succinatos/farmacología , Replicación Viral/efectos de los fármacosRESUMEN
The human immunodeficiency virus type 1 (HIV-1) Vpu and Env proteins are expressed from a bicistronic mRNA. To address the biological significance of the coordinated expression of vpu and env, we compared the relative effects on particle release of HIV-1 isolates containing an intact vpu gene or carrying point mutations in its initiation codon or internal deletions, respectively. We found that the primary AD8 isolate, which is unable to express vpu due to a mutation in its translation initiation codon, was able to replicate in primary macrophages and peripheral blood mononuclear cells with efficiency similar to that of an isogenic variant expressing Vpu. Interestingly, AD8 lacking a vpu initiation codon produced higher levels of Env protein than its Vpu-expressing isogenic variant. In contrast, disabling Vpu without removing the vpu initiation codon did not alter Env expression but significantly reduced virus production. AD8 Env when provided in trans was capable of enhancing release not only of AD8 particles but also of viruses of the T-cell-tropic NL4-3 isolate. We conclude that AD8 Env encodes a Vpu-like activity similar to that previously reported for HIV-2 Env proteins and is thus able to augment virus secretion. When expressed at elevated levels, i.e., following mutation of the vpu initiation codon, AD8 Env was able to compensate for the lack of Vpu and thereby ensure efficient virus release. Thus, the ability to regulate virus release is redundant in AD8 and can be controlled by either Vpu or Env. Since Vpu controls several independent functions, including CD4 degradation, our results suggest that some HIV-1 isolates may have evolved a mechanism to regulate Vpu activity without compromising their ability to efficiently replicate in the host cells.
Asunto(s)
Productos del Gen env/fisiología , VIH-1/fisiología , Macrófagos/virología , Proteínas Reguladoras y Accesorias Virales/fisiología , Secuencia de Aminoácidos , Secuencia de Bases , Células Cultivadas , Expresión Génica , Productos del Gen env/biosíntesis , VIH-1/genética , VIH-1/aislamiento & purificación , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/virología , Macrófagos/citología , Datos de Secuencia Molecular , Mutagénesis , Transfección , Proteínas Reguladoras y Accesorias Virales/genética , Replicación ViralRESUMEN
In addition to its role in receptor binding, the envelope glycoprotein of certain human immunodeficiency virus type 2 (HIV-2) isolates, including ROD10, exhibits a biological activity that enhances the release of HIV-2, HIV-1, and simian immunodeficiency virus particles from infected cells. The present study aims at better defining the functional domains involved in this biological activity. To this end, we have characterized the envelope protein of the ROD14 isolate of HIV-2, which, despite 95% homology with the ROD10 envelope at the amino acid level, is unable to enhance viral particle release. Site-directed mutagenesis showed that the presence of a truncation in the cytoplasmic tail of the ROD14 envelope was not responsible for the lack of activity, as previously reported for the HIV-2 ST isolate (G. D. Ritter, Jr., G. Yamshchikov, S. J. Cohen, and M. J. Mulligan, J. Virol. 70:2669-2673, 1996). Similarly, several modifications of the length of the ROD10 envelope cytoplasmic tail did not impair its ability to enhance particle release, suggesting that, in the case of the HIV-2 ROD isolate, particle release activity is not regulated by the length of the cytoplasmic tail.
Asunto(s)
Productos del Gen env/fisiología , Herpesvirus Humano 2/fisiología , Virión/fisiología , Secuencia de Aminoácidos , Citoplasma , Productos del Gen env/química , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Relación Estructura-ActividadRESUMEN
HIV-1 Vpu interacts with CD4 in the endoplasmic reticulum and triggers CD4 degradation, presumably by proteasomes. Human beta TrCP identified by interaction with Vpu connects CD4 to this proteolytic machinery, and CD4-Vpu-beta TrCP ternary complexes have been detected by coimmunoprecipitation. beta TrCP binding to Vpu and its recruitment to membranes require two phosphoserine residues in Vpu essential for CD4 degradation. In beta TrCP, WD repeats at the C terminus mediate binding to Vpu, and an F box near the N terminus is involved in interaction with Skp1p, a targeting factor for ubiquitin-mediated proteolysis. An F-box deletion mutant of beta TrCP had a dominant-negative effect on Vpu-mediated CD4 degradation. These data suggest that beta TrCP and Skp1p represent components of a novel ER-associated protein degradation pathway that mediates CD4 proteolysis.
Asunto(s)
Antígenos CD4/metabolismo , Retículo Endoplásmico/metabolismo , Proteínas de Unión al GTP/genética , VIH-1 , Proteínas Reguladoras y Accesorias Virales/metabolismo , Sitios de Unión/inmunología , Proteínas de Ciclo Celular/metabolismo , Retículo Endoplásmico/química , Retículo Endoplásmico/virología , Proteínas de Unión al GTP/química , Proteínas de Unión al GTP/metabolismo , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Células Jurkat , Datos de Secuencia Molecular , Mutagénesis/fisiología , Secuencias Repetitivas de Ácidos Nucleicos , Proteínas Quinasas Asociadas a Fase-S , Homología de Secuencia de Aminoácido , Serina/metabolismo , Ubiquitinas/metabolismo , Proteínas con Repetición de beta-TransducinaRESUMEN
The human immunodeficiency virus type 1 (HIV-1) vpu gene encodes a type I anchored integral membrane phosphoprotein with two independent functions. First, it regulates virus release from a post-endoplasmic reticulum (ER) compartment by an ion channel activity mediated by its transmembrane anchor. Second, it induces the selective down regulation of host cell receptor proteins (CD4 and major histocompatibility complex class I molecules) in a process involving its phosphorylated cytoplasmic tail. In the present work, we show that the Vpu-induced proteolysis of nascent CD4 can be completely blocked by peptide aldehydes that act as competitive inhibitors of proteasome function and also by lactacystin, which blocks proteasome activity by covalently binding to the catalytic beta subunits of proteasomes. The sensitivity of Vpu-induced CD4 degradation to proteasome inhibitors paralleled the inhibition of proteasome degradation of a model ubiquitinated substrate. Characterization of CD4-associated oligosaccharides indicated that CD4 rescued from Vpu-induced degradation by proteasome inhibitors is exported from the ER to the Golgi complex. This finding suggests that retranslocation of CD4 from the ER to the cytosol may be coupled to its proteasomal degradation. CD4 degradation mediated by Vpu does not require the ER chaperone calnexin and is dependent on an intact ubiquitin-conjugating system. This was demonstrated by inhibition of CD4 degradation (i) in cells expressing a thermally inactivated form of the ubiquitin-activating enzyme E1 or (ii) following expression of a mutant form of ubiquitin (Lys48 mutated to Arg48) known to compromise ubiquitin targeting by interfering with the formation of polyubiquitin complexes. CD4 degradation was also prevented by altering the four Lys residues in its cytosolic domain to Arg, suggesting a role for ubiquitination of one or more of these residues in the process of degradation. The results clearly demonstrate a role for the cytosolic ubiquitin-proteasome pathway in the process of Vpu-induced CD4 degradation. In contrast to other viral proteins (human cytomegalovirus US2 and US11), however, whose translocation of host ER molecules into the cytosol occurs in the presence of proteasome inhibitors, Vpu-targeted CD4 remains in the ER in a transport-competent form when proteasome activity is blocked.
Asunto(s)
Antígenos CD4/metabolismo , Cisteína Endopeptidasas/metabolismo , Glicoproteínas/metabolismo , VIH-1/metabolismo , Complejos Multienzimáticos/metabolismo , Ubiquitinas/metabolismo , Proteínas Reguladoras y Accesorias Virales/metabolismo , Acetilcisteína/análogos & derivados , Acetilcisteína/farmacología , Antígenos CD4/genética , Proteínas de Unión al Calcio/genética , Proteínas de Unión al Calcio/metabolismo , Calnexina , Línea Celular , Inhibidores de Cisteína Proteinasa/farmacología , Citoplasma , Citosol/metabolismo , Activación Enzimática , Glicoproteínas/genética , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Leupeptinas/farmacología , Mutagénesis , Complejo de la Endopetidasa Proteasomal , Proteínas Reguladoras y Accesorias Virales/genéticaRESUMEN
We have recently shown that the envelope glycoprotein of the ROD10 isolate of human immunodeficiency virus type 2 (HIV-2) has the ability to positively regulate HIV-2 viral particle release. The activity provided by the ROD10 Env was remarkably similar to that of the HIV-1 Vpu protein, thus raising the possibility that the two proteins act in a related fashion. We now show that the ROD10 Env can functionally replace Vpu to enhance the rate of HIV-1 particle release. When provided in trans, both Vpu and the ROD10 Env restored wild-type levels of particle release in a Vpu-deficient mutant of the NL4-3 molecular clone with indistinguishable efficiencies. This effect was independent of the presence of the HIV-1 envelope protein. The ROD10 Env also enhanced HIV-1 particle release in the context of HIV-2 chimeric viruses containing the HIV-1 gag-pol, indicating a lack of need for additional HIV-1 products in this process. In addition, we show for the first time that HIV-1 Vpu, as well as ROD10 Env, has the ability to enhance simian immunodeficiency virus (SIV) particle release. The effects of Vpu and ROD10 Env on SIV particle release were indistinguishable and were observed in the context of full-length SIVmac239 and simian-human immunodeficiency virus chimeras. These results further demonstrate that ROD10 Env can functionally complement Vpu with respect to virus release. In contrast, we found no evidence of a destabilizing activity of ROD10 Env on the CD4 molecule. HIV-1 and HIV-2 thus appear to have evolved genetically distinct but functionally similar strategies to resolve the common problem of efficient release of progeny virus from infected cells.
Asunto(s)
Productos del Gen env/metabolismo , VIH-1/metabolismo , VIH-2/metabolismo , Precursores de Proteínas/metabolismo , Proteínas Reguladoras y Accesorias Virales/metabolismo , Animales , Antígenos CD4/inmunología , Regulación Viral de la Expresión Génica , Productos del Gen env/genética , Productos del Gen env/inmunología , VIH-1/genética , VIH-1/fisiología , VIH-2/genética , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Precursores de Proteínas/genética , Precursores de Proteínas/inmunología , Conejos , Virus Reordenados/genética , Virus Reordenados/metabolismo , Virus Reordenados/fisiología , Proteínas Reguladoras y Accesorias Virales/genética , Ensamble de Virus , Productos del Gen env del Virus de la Inmunodeficiencia HumanaRESUMEN
HIV-1 Vpu catalyzes two independent functions, degradation of the virus receptor CD4 in the endoplasmic reticulum and enhancement of virus release from the cell surface. These activities are confined to distinct structural domains of Vpu, the cytoplasmic tail and the transmembrane (TM) anchor, respectively. It was recently reported that Vpu forms cation-selective ion channels in lipid bilayers. Here we report that this property of Vpu is a characteristic of its TM anchor. Expression of full-length Vpu in Xenopus oocytes increases membrane conductance. The Vpu-induced conductance is selective to monovalent cations over anions, does not discriminate Na+ over K+ and shows marginal permeability to divalent cations. Notably, introduction of the scrambled TM sequence into full-length Vpu abrogates its capacity to increase membrane conductance in oocytes and to promote virus release from infected cells. Reconstitution of synthetic Vpu fragments in lipid bilayers identified an ion channel activity for a sequence corresponding to the TM domain of Vpu. In contrast, a peptide with the same amino acid composition but with a scrambled sequence does not form ion channels. Our findings therefore suggest that the ability of Vpu to increase virus release from infected cells may be correlated with an ion channel activity of the TM domain, thereby providing a potential target for drug intervention based on the development of Vpu-specific channel blockers.
Asunto(s)
Membrana Celular/metabolismo , VIH-1/metabolismo , Canales Iónicos/metabolismo , Oocitos/virología , Proteínas Reguladoras y Accesorias Virales/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Cationes/metabolismo , Membrana Celular/virología , Permeabilidad de la Membrana Celular , Electrofisiología , Femenino , VIH-1/química , Proteínas del Virus de la Inmunodeficiencia Humana , Membrana Dobles de Lípidos , Datos de Secuencia Molecular , Oocitos/metabolismo , Oocitos/ultraestructura , Conformación Proteica , Proteínas Reguladoras y Accesorias Virales/química , Proteínas Reguladoras y Accesorias Virales/genética , XenopusRESUMEN
The human immunodeficiency virus type 1 (HIV-1) Vpu protein is an integral membrane phosphoprotein that induces CD4 degradation in the endoplasmic reticulum and enhances virus release from the cell surface. CD4 degradation is specific, requires phosphorylation of Vpu, and involves the interaction between Vpu and the CD4 cytoplasmic domain. In contrast, regulation of virus release is less specific and not restricted to HIV-1 and may be mechanistically-distinct from CD4 degradation. We show here that a mutant of Vpu, Vpu35, lacking most of its cytoplasmic domain has residual biological activity for virus release but is unable to induce CD4 degradation. This finding suggests that the N terminus of Vpu encoding the transmembrane (TM) anchor represents an active domain important for the regulation of virus release but not CD4 degradation. To better define the functions of Vpu's TM anchor and cytoplasmic domain, we designed a mutant, VpuRD, containing a scrambled TM sequence with a conserved amino acid composition and alpha-helical structure. The resulting protein was integrated normally into membranes, was able to form homo-oligomers, and exhibited expression levels, protein stability, and subcellular localization similar to those of wild-type Vpu. Moreover, VpuRD was capable of binding to CD4 and to induce CD4 degradation with wild-type efficiency, confirming proper membrane topology and indicating that the alteration of the Vpu TM domain did not interfere with this function of Vpu. However, VpuRD was unable to enhance the release of virus particles from infected or transfected cells, and virus encoding VpuRD had replication characteristics in T cells indistinguishable from those of a Vpu-deficient HIV-1 isolate. Mutation of the phosphorylation sites in VpuRD resulted in a protein which was unable to perform either function of Vpu. The results of our experiments suggest that the two biological activities of Vpu operate via two distinct molecular mechanisms and involve two different structural domains of the Vpu protein.
Asunto(s)
VIH-1/metabolismo , Proteínas Reguladoras y Accesorias Virales/metabolismo , Secuencia de Aminoácidos , Animales , Sitios de Unión , Antígenos CD4/metabolismo , Seropositividad para VIH/sangre , Seropositividad para VIH/inmunología , VIH-1/aislamiento & purificación , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Proteínas de la Membrana/química , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Proteínas Reguladoras y Accesorias Virales/química , Proteínas Reguladoras y Accesorias Virales/genética , Virión/metabolismoRESUMEN
The Vpu protein is a human immunodeficiency virus type 1 (HIV-1)-specific accessory protein that is required for the efficient release of viral particles from infected cells. Even though HIV-2 does not encode Vpu, we found that this virus is nevertheless capable of efficiently releasing virus particles. In fact, the rate of virus release from HeLa cells transfected with a full-length molecular clone of HIV-2, ROD10, was comparable to that observed for the vpu+ HIV-1 NL4-3 isolate and was not further enhanced by expression of Vpu in trans. However, consistent with previous observations showing that HIV-2 particle release is Vpu responsive in the context of HIV-1/HIV-2 chimeric constructs; exchanging the gag-pol region of NL4-3 with the corresponding region from pROD10 rendered the resulting chimeric virus Vpu responsive. Our finding that the responsiveness of HIV-2 particle release to Vpu is context dependent suggested the presence of a Vpu-like factor(s) encoded by HIV-2. Using chimeric proviruses encoding HIV-2 gag and pol in the context of the HIV-1 provirus that were coexpressed with subgenomic HIV-2 constructs, we found that the HIV-2 envelope glycoprotein had the ability to enhance HIV-2 particle release with an efficiency comparable to that of the HIV-1 Vpu protein. Conversely, inactivation of the HIV-2 env gene in the original ROD10 clone resulted in a decrease in the rate of viral particle release to a level that was comparable to that of Vpu-deficient HIV-1 isolates. Providing the wild-type envelope in trans rescued the particle release defect of the ROD10 envelope mutant. Thus, unlike HIV-1, which encodes two separate proteins to regulate virus release or to mediate viral entry, the HIV-2 Env protein has evolved to perform both functions.
Asunto(s)
Glicoproteínas/metabolismo , VIH-2/metabolismo , Proteínas del Envoltorio Viral/metabolismo , Proteínas Reguladoras y Accesorias Virales/metabolismo , Brefeldino A , Ciclopentanos/farmacología , Productos del Gen nef/metabolismo , Productos del Gen vif/metabolismo , Productos del Gen vpr/metabolismo , Genes Virales , Glicoproteínas/efectos de los fármacos , Glicoproteínas/genética , Seropositividad para VIH/sangre , Seropositividad para VIH/inmunología , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Mutación , Proteínas del Envoltorio Viral/efectos de los fármacos , Proteínas del Envoltorio Viral/genética , Proteínas Reguladoras y Accesorias Virales/efectos de los fármacos , Virión/metabolismo , Productos del Gen nef del Virus de la Inmunodeficiencia Humana , Productos del Gen vif del Virus de la Inmunodeficiencia Humana , Productos del Gen vpr del Virus de la Inmunodeficiencia HumanaRESUMEN
The human immunodeficiency virus type 1 (HIV-1) Vif protein has an important role in the regulation of virus infectivity. This function of Vif is cell type specific, and virions produced in the absence of Vif in restrictive cells have greatly reduced infectivity. We show here that the intracellular localization of Vif is dependent on the presence of the intermediate filament vimentin. Fractionation of acutely infected T cells or transiently transfected HeLa cells demonstrates the existence of a soluble and a cytoskeletal form and to a lesser extent the presence of a detergent-extractable form of Vif. Confocal microscopy suggests that in HeLa cells, Vif is predominantly present in the cytoplasm and closely colocalizes with the intermediate filament vimentin. Treatment of cells with drugs affecting the structure of vimentin filaments affect the localization of Vif accordingly, indicating a close association of Vif with this cytoskeletal component. The association of Vif with vimentin can cause the collapse of the intermediate filament network into a perinuclear aggregate. In contrast, analysis of Vif in vimentin-negative cells reveals significant staining of the nucleus and the nuclear membrane in addition to diffuse cytoplasmic staining. In addition to the association of Vif with intermediate filaments, analyses of virion preparations demonstrate that Vif is incorporated into virus particles. In sucrose density gradients, Vif cosediments with capsid proteins even after detergent treatment of virus preparations, suggesting that Vif is associated with the inner core of HIV particles. We propose a model in which Vif has a crucial function as a virion component either by regulating virus maturation or following virus entry into a host cell possibly involving an interaction with the cellular cytoskeletal network.
Asunto(s)
Citoesqueleto/virología , Productos del Gen vif/metabolismo , VIH-1/metabolismo , Vimentina/metabolismo , Animales , Secuencia de Bases , Línea Celular , Citoesqueleto/metabolismo , ADN Viral , Seropositividad para VIH/sangre , Seropositividad para VIH/inmunología , Células HeLa , Humanos , Datos de Secuencia Molecular , Células Tumorales Cultivadas , Virión/metabolismo , Productos del Gen vif del Virus de la Inmunodeficiencia HumanaRESUMEN
The human immunodeficiency virus type 1-specific Vpu protein is a small integral membrane phosphoprotein that induces degradation of the virus receptor CD4 in the endoplasmic reticulum and, independently, increases the release of progeny virions from infected cells. To address the importance of Vpu for virus replication in primary human cells such as peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM), we used three different sets of monocyte-tropic molecular clones of human immunodeficiency virus type 1: a primary isolate, AD8+, and two chimeric variants of the T-cell-tropic isolate NL4-3 carrying the env determinants of either AD8+ or SF162 monocyte-tropic primary isolates. Isogenic variants of these chimeric viruses were constructed to express either wild-type Vpu or various mutants of Vpu. The effects of these mutations in the vpu gene on virus particle secretion from infected MDM or PBMC were assessed by determination of the release of virion-associated reverse transcriptase into culture supernatants, Western blot (immunoblot) analysis of pelleted virions, and steady-state or pulse-chase metabolic labeling. Wild-type Vpu increased virus release four- to sixfold in MDM and two- to threefold in PBMC, while nonphosphorylated Vpu and a C-terminal truncation mutant of Vpu were partially active on virus release in primary cells. These results demonstrate that Vpu regulates virus release in primary lymphocyte and macrophage cultures in a similar manner and to a similar extent to those previously observed in HeLa cells or CD4+ T-cell lines. Thus, our findings provide evidence that Vpu functions in a variety of human cells, both primary cells and continuous cell lines, and mutations in Vpu affect its biological activity independent of the cell type and virus isolate used.
Asunto(s)
VIH-1/fisiología , Linfocitos/virología , Macrófagos/virología , Proteínas Reguladoras y Accesorias Virales/metabolismo , Replicación Viral , Células Cultivadas , Clonación Molecular , Expresión Génica , Genoma Viral , Seronegatividad para VIH , VIH-1/genética , Células HeLa , Proteínas del Virus de la Inmunodeficiencia Humana , Humanos , Cinética , Monocitos/virología , Provirus/genética , Provirus/fisiología , Factores de Tiempo , Transfección , Proteínas Reguladoras y Accesorias Virales/biosíntesis , Proteínas Reguladoras y Accesorias Virales/aislamiento & purificaciónRESUMEN
We have recently demonstrated that coexpression of Vpu and CD4 in HeLa cells results in the degradation of CD4 in the endoplasmic reticulum. The sensitivity of CD4 to Vpu-mediated degradation is conferred by the presence of specific sequences located between amino acids 402 and 420 in the CD4 cytoplasmic domain. Using an in vitro translation system, we also showed that degradation of CD4 by Vpu requires the two proteins to be present in the same membrane compartment. Although these results suggest that spatial proximity between CD4 and Vpu may be critical in triggering degradation, it remains unknown whether the two molecules have the ability to interact with each other. In order to better define the mechanisms involved in CD4 degradation, we investigated the existence and functional relevance of direct interactions between CD4 and Vpu. Coimmunoprecipitation experiments showed that Vpu specifically binds to the cytoplasmic tail of CD4. This phenomenon is relevant to the mechanism of CD4 degradation since the ability of CD8/CD4 chimeric molecules and various CD4 mutants to form complexes with Vpu correlates with their sensitivity to degradation. Accordingly, we found that amino acid residues in the CD4 cytoplasmic tail previously shown to be important for degradation are necessary for Vpu binding. We further demonstrate that a deletion mutant of Vpu as well as a phosphorylation mutant, both biologically inactive with regard to CD4 degradation, retained the capacity to interact with the CD4 cytoplasmic domain. Taken together, these results indicate that Vpu binding is necessary to trigger CD4 degradation. However, the binding to target molecules is not sufficient per se to cause degradation. Interaction between CD4 and Vpu is thus likely to be an early event critical in triggering a multistep process leading to CD4 degradation.